MEDIA ADVISORY, July 25, 2006 (PRIMEZONE) --
What: Mark Pykett, President of Boston Life Sciences, Inc. (BLSI) will preside over the closing bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Wednesday, July 26th, 2006 at 4:00 p.m. EDT Contacts: Media: Sharon Correia, Director, Corporate Communication & IR (508) 497-2360 x224 (508) 314-3155 (Cell) scorreia@bostonlifesciences.com Investors: Meredith Patin, Investor Relations Associate (508) 497-2360 x239 (617) 314-2951 (Cell) mpatin@bostonlifesciences.com NASDAQ MarketSite: Stephanie Lowenthal; (646) 441-5220
Feed Information:
The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8 The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Boston Life Sciences, Inc. (BLSI):
Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials as an aid in the diagnosis of Parkinson's Disease and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine to promote functional recovery following stroke and spinal cord injury, a DAT blocker for the treatment of Parkinson's disease, oncomodulin for regeneration of the optic nerve and a second generation technetium-based molecular imaging agent for diagnosing Parkinson's Disease and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston.